ORIENT-11: Sintilimab plus Pemetrexed plus Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC

被引：0
|
作者：
Zhang, L. [1 ]
Yang, Y. [1 ]
Wang, Z. [2 ]
Fang, J. [3 ]
Yu, Q. [4 ]
Han, B. [5 ]
Cang, S. [6 ]
Chen, G. [7 ]
Mei, X. [8 ]
Yang, Z. [9 ]
Ma, R. [10 ]
Bi, M. [11 ]
Ren, X. [12 ]
Zhou, J. [13 ]
Li, B. [14 ]
Xu, W. [15 ]
Ji, Y. [15 ]
Peng, B. [15 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Shandong Prov Canc Hosp, Jinan, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing, Peoples R China
[4] Tumor Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[5] Shanghai Chest Hosp, Shanghai, Peoples R China
[6] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[8] Anhui Prov Hosp, Hefei, Peoples R China
[9] Guangdong Med Univ, Affiliated Hosp, Guangzhou, Peoples R China
[10] Liaoning Canc Hosp, Shenyang, Peoples R China
[11] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[12] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[13] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China
[15] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 10期
关键词：
anti-PD-1; antibody; chemotherapy; nsqNSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ID:1329
引用
收藏
页码：E41 / E41
页数：1
相关论文
共 50 条
  • [41] KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
    Gadgeel, S.
    Rodriguez-Abreu, D.
    Felip, E.
    Esteban, E.
    Speranza, G.
    Reck, M.
    Hui, R.
    Boyer, M.
    Garon, E. B.
    Horinouchi, H.
    Cristescu, R.
    Aurora-Garg, D.
    Lunceford, J.
    Kobie, J.
    Ayers, M.
    Piperdi, B.
    Pietanza, M. C.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 64 - 65
  • [42] RANDOMIZED PHASE-3 TRIAL (INSPIRE) OF NECITUMUMAB PLUS CISPLATIN-PEMETREXED VERSUS CISPLATIN-PEMETREXED ALONE AS FIRST-LINE THERAPY IN STAGE IV NON-SQUAMOUS NSCLC
    Paz-Ares, Luis
    Mezger, Jorg
    Ciuleanu, Tudor
    Fischer, Jurgen R.
    Von Pawel, Joachim
    Provencio, Mariano
    Kazarnowicz, Andrzej
    Losonczy, Gyoergy
    Castro, Gilberto, Jr.
    Szczesna, Aleksandra
    Crino, Lucio
    Reck, Martin
    Ramlau, Rodryg
    Ulsperger, Ernst
    Schumann, Christian
    Miziara, Jose E.
    Lessa, Alvaro
    Depenbrock, Henrik
    Soldatenkova, Victoria
    Balint, Beatrix
    Hirsch, Fred R.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S139 - S140
  • [43] Gemcitabine Plus Irinotecan as First-Line Weekly Therapy in Locally Advanced and/or Metastatic Pancreatic Cancer
    Neri, B.
    Cipriani, G.
    Grifoni, R.
    Molinara, E.
    Pantaleo, P.
    Rangan, S.
    Vannini, A.
    Tonelli, P.
    Valeri, A.
    Pantalone, D.
    Taddei, A.
    Bechi, P.
    ONCOLOGY RESEARCH, 2009, 17 (11-12) : 559 - 564
  • [44] Carboplatin plus paclitaxel as first-line therapy for locally advanced recurrent metastatic endometrial cancer
    Attarian, H.
    Rezvani, H.
    Ghadyani, M.
    Okhovatian, A.
    Khosravi, A.
    Attarian, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Health-Related Quality of Life with Pembrolizumab or Placebo plus Pemetrexed plus Platinum in Non-Squamous NSCLC: KEYNOTE-189
    Garassino, M.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    Speranza, G.
    Domine, M.
    Hochmair, M.
    Powell, S.
    Cheng, S.
    Bischoff, H.
    Peled, N.
    Reck, M.
    Hui, R.
    Garon, E.
    Boyer, M.
    Yang, J.
    Burke, T.
    Pietanza, M. C.
    Gandhi, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S155 - S155
  • [46] Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
    Liu, Lulu
    Wang, Lei
    Chen, Li
    Ding, Yiling
    Zhang, Qilin
    Shu, Yamin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN
    Hou, X.
    Zhou, C.
    Wu, G.
    Lin, W.
    Xie, Z.
    Zhang, H.
    Yi, J.
    Peng, Z.
    Yin, L.
    Ma, C.
    Chen, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S318 - S318
  • [48] First-Line Icotinib Versus Cisplatine/Pemetrexed Plus Pemetrexed Maintenance in Advanced NSCLC Patients with EGFR Mutation
    Shi, Yuankai
    Wang, Lin
    Han, Baohui
    Li, Wei
    Yu, Ping
    Liu, Yunpeng
    Ding, Cuimin
    Song, Xia
    Ma, Zhiyong
    Ren, Xinling
    Feng, Jifeng
    Zhang, Helong
    Chen, Gongyan
    Wu, Ning
    Han, Xiaohong
    Yao, Chen
    Song, Yong
    Zhang, Shucai
    Ding, Lieming
    Tan, Fenlai
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S205 - S206
  • [49] Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study
    Horinouchi, H.
    Nogami, N.
    Saka, H.
    Nishio, M.
    Tokito, T.
    Takahashi, T.
    Kasahara, K.
    Hattori, Y.
    Ichihara, E.
    Adachi, N.
    Sawada, T.
    Shimamoto, T.
    Noguchi, K.
    Pietanza, M. C.
    Kurata, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer
    Xu, Bei
    Liu, Peng
    Yin, Yongmei
    Liu, Ping
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (08) : 763 - 769
12345